RedPath Integrated Pathology today announced the execution of an agreement with preferred provider organization MultiPlan for RedPath’s PathFinder TG test for pancreatic cancer.
The contract is the seventh inked by the Pittsburgh-based molecular diagnostics firm with a national PPO and expands the number of covered lives for the test to more than 74 million people, RedPath said. PathFinder TG produces mutational profiles to help physicians “resolve complex diagnostic dilemmas in patients who are at risk of cancer.”
RedPath performs the test in its CLIA-certified and CAP-accredited laboratory.
MultiPlan said on its website that it has more than 900,000 healthcare providers under contract. About 68 million consumers have access to the PPO’s products.
Comments are closed.